Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
UNC Lineberger Comprehensive Cancer Center
Study ID
NCT05743426
Status
Recruiting
Apply to this trial

Conditions

  • Gastrointestinal Cancer
  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Survey — OTHER
    Patient Reported Outcome (PRO) questionnaire
  • Toxicity Assessments — OTHER
    Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).

Study Details

This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.

Key Dates

Start date
Mar 17, 2023
Status verified
Mar 2026
Primary completion
Jan 1, 2036
Completion
Jan 1, 2036

Study Design

Enrollment
180 participants (estimated)

Arms

  • Arm: Single Arm
    Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.

Primary Outcome Measure

Disease-free survival [ Time Frame: Up to 10 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel HillNorth Carolina27599
Victoria Xu
[email protected]
984-974-8744
Theodore K Yanagihara, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chapel Hill, NC

By research site
University of North Carolina at Chapel Hill, Department of Radiation Oncology· Chapel Hill, NC

Related Studies